82952-64-5 Usage
Description
Trimetrexate glucuronate is a nonclassical antifolate drug that has been introduced in the U.S.A. and Canada as a second-line therapy for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis in AIDS patients who are refractory or intolerant to co-trimoxazole therapy. It is also in clinical trials for the treatment of various types of cancer and other conditions such as psoriasis and rheumatoid arthritis. The drug works by inhibiting the enzyme dihydrofolate reductase, which disrupts DNA, RNA, and protein synthesis, leading to cell death.
Uses
Used in Antineoplastic Applications:
Trimetrexate glucuronate is used as an antineoplastic agent for the treatment of several types of cancer, including colorectal, gastric, pancreas, prostate, bladder, lung, breast, head, and neck cancers. It inhibits the enzyme dihydrofolate reductase, which is essential for DNA synthesis and cell proliferation, leading to the disruption of cancer cell growth and induction of cell death.
Used in Treatment of Pneumocystis carinii Pneumonia (PCP):
Trimetrexate glucuronate is used as a second-line therapy for the treatment of Pneumocystis carinii pneumonia (PCP) in AIDS patients who are refractory or intolerant to co-trimoxazole therapy. It helps in managing the infection and improving the patient's condition.
Used in Treatment of Toxoplasmosis:
Trimetrexate glucuronate is also used for the treatment of toxoplasmosis in AIDS patients who are refractory or intolerant to co-trimoxazole therapy. It helps in controlling the infection and reducing the symptoms associated with the disease.
Used in Clinical Trials for Other Conditions:
Trimetrexate glucuronate is in early clinical trials for topical use in treating psoriasis and as an oral drug to treat rheumatoid arthritis. Its potential applications in these conditions are being explored to determine its efficacy and safety.
Used in Drug Development:
CI 898 Glucuronate is a dihydrofolate reductase (DHFR) inhibitor, which is a similar mechanism of action as Trimetrexate glucuronate. It is being studied for its potential use in the development of new drugs targeting various diseases.
Manufacturing Process
A mixture of 2,4-diamino-5-methyl-6-[(3,4,5-
trimethoxyanilino)methyl]quinazoline (1.0 g) and glucuronic acid (0.7 g) in
methanol (65 ml) is heated to dissolve the solid. The solution is cooled to
10°C and filtered to remove a small amount of solid. The filtrate is heated to
reflux and ethyl acetate is added to the cloud point. The warm solution is
filtered then slowly cooled. The solid that forms is collected, washed first with
ethylacetate, then with ether and dried in vacuo at 60°C to give the 4-
diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline D_x0002_glucuronate as a yellow powder with no definite melting point.
Therapeutic Function
Antineoplastic
Biological Activity
Potent lipophilic inhibitor of dihydrofolate reductase (DHFR) that displays antineoplastic and antiprotozoal properties. Inhibits protozoal, bacterial and human DHFR with IC 50 values of 1.4, 6.1 and 3.2 nM respectively. Affects G 1 /S phase cell cycle progression.
Check Digit Verification of cas no
The CAS Registry Mumber 82952-64-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,9,5 and 2 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 82952-64:
(7*8)+(6*2)+(5*9)+(4*5)+(3*2)+(2*6)+(1*4)=155
155 % 10 = 5
So 82952-64-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H23N5O3.C6H10O7/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;7-1-2(8)3(9)4(10)5(11)6(12)13/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);1-5,8-11H,(H,12,13)/t;2-,3+,4-,5-/m.0/s1
82952-64-5Relevant articles and documents
2-4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline salts
-
, (2008/06/13)
2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline salts, pharmaceutical compositions containing said salts, methods of treating malaria, and bacterial infections employing said salts and compositions and methods for producing said salts.
